The Pharmacist’s Role in Opioid Analgesia: Supporting the Pain Patient While Preventing Overdose, Misuse, and Diversion

Mara N. Villanueva, PharmD
Published Online: Wednesday, July 16, 2014
Follow Pharmacy_Times:
This activity is supported by educational grants from Purdue Pharma LP, Teva Pharmaceuticals, and Zogenix, Inc.

The Pharmacist’s Role in Opioid Analgesia: Supporting the Pain Patient While Preventing Overdose, Misuse, and Diversion

Faculty
Mara N. Villanueva, PharmD
Clinical Pharmacy Specialist
Pharmacy Medication Management
and Analytics
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Educational Objectives
At the conclusion of this educational activity, participants should be able to:
  • Examine the risk factors associated with the highest rates of opioid overdose.
  • Identify the characteristics and red flags of patients who intend to use or distribute opioids for non-medical reasons.
  • Review the information that is important to communicate to patients regarding appropriate opioid medication use, storage, and disposal.
  • Describe how pharmacists can support the current Risk Evaluation and Mitigation Strategy programs for extended-release, long-acting, and transmucosal immediate-release fentanyl opioid products, and identify the tools available to prevent opioid misuse, diversion, and abuse.
Intended Audience
Pharmacists

Release date: July 8, 2014
Expiration date: July 8, 2016
Estimated time to complete activity: 1.5 hours
Fee: Free

Click here to view this activity.
Click here to view this activity. - See more at: http://www.pharmacytimes.com/publications/issue/2014/June2014/Optimizing-the-Management-of-Asthma-The-Critical-Role-of-the-Pharmacist#sthash.7ZeRdjp8.dpuf
Click here to view this activity.

Description: Pharmacy Times/Ascend Media Office of Continuing Professional EducationPharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-14-062-H03-P. The activity is available for CE credit through July 8, 2016.

Related Articles
Drugs that contain hydrocodone will be moved to a more restrictive category of the Controlled Substances Act.
Aspirin not only prevents the production of pain-causing compounds in the body, but also triggers an enzyme to speed the reduction of inflammation.
Galleon Pharmaceuticals Corp's GAL-021 reverses and prevents respiratory depression associated with opioid use without affecting analgesia.
Latest Issues
$auto_registration$